Novartis Ag (NVS) Property, Plant & Equipment (Net) Growth (3y) (2012 - 2026)
Novartis Ag (NVS) Property, Plant & Equipment (Net) Growth (3y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PP&E (Net) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 4.65% |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 5.45% |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 5.00% |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 6.91% |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 6.03% |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 15.61% |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 1.73% |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 2.85% |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 5.03% |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 119.81% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 106.04% |
| Dec 31, 2025 | 95.55% |
| Jun 30, 2025 | 827.72% |
| Dec 31, 2024 | -87.99% |
| Jun 30, 2024 | -45.61% |
| Dec 31, 2023 | -8.11% |
| Jun 30, 2023 | 646.71% |
| Dec 31, 2022 | -26.40% |
| Jun 30, 2022 | -33.40% |
| Mar 31, 2022 | -32.88% |
| Dec 31, 2021 | -30.25% |
| Jun 30, 2021 | -0.17% |
| Dec 31, 2020 | -28.82% |
| Sep 30, 2020 | -89.19% |
| Jun 30, 2020 | -92.30% |
| Dec 31, 2019 | -4.80% |
| Dec 31, 2018 | -32.10% |
| Jun 30, 2018 | 193,221.11% |
| Dec 31, 2017 | -27.11% |
| Dec 31, 2016 | -31.11% |